Amicus Therapeutics is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
The therapeutic focus of Amicus is on rare and orphan diseases, particularly disorders collectively called lysosomal storage disorders.:2 The company has focused on pharmacological chaperones and enzyme replacement therapy.:2,18:95
In 2008, the company expanded from its single site in New Jersey to a second research site in San Diego.
In late 2009, the company faced a major financial setback with the termination of a multi-year collaboration agreement with Shire for its lead compound, migalastat, and two other products.:24 Amicus cut 20% of its workforce.:24
The next year, the company signed an exclusive license agreement with GlaxoSmithKline for miglastat; GSK paid $60 million in upfront and equity payments while promising up to $170 million to help develop their products, GSK terminated the arrangement in 2013.
In November 2013, Amicus acquired competitor Callidus Biopharma for its enzyme replacement therapy treatment for Pompe disease.:3,12
Highest paying job titles at Amicus Therapeutics include Marketing Manager, Global Marketing Manager, and Quality Control Manager